We narrowed to 109,629 results for: Ran;

1. pAAV-synP-FLEX-splitTVA-EGFP-B19G (AAV1)

   Viral Prep

   #52473-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-synP-FLEX-splitTVA-EGFP-B19G (#52473). In addition to the viral particles, you will also receive purified pAAV-synP-FLEX-splitTVA-EGFP-B19G plasmid DNA. Helper virus for monosynaptic tracing with rabies virus. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ian Wickersham

   Article

   Kohara et al Nat Neurosci. 2014 Feb;17(2):269-79. doi

   Promoter

   Syn

   Tags

   EGFP (Cre-dependent)

   Available since

   Dec. 18, 2018

   Availability

   Academic Institutions and Nonprofits only

2. pAAV-synP-FLEX-splitTVA-EGFP-B19G (AAV1)

   Viral Prep

   #52473-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-synP-FLEX-splitTVA-EGFP-B19G (#52473). In addition to the viral particles, you will also receive purified pAAV-synP-FLEX-splitTVA-EGFP-B19G plasmid DNA. Helper virus for monosynaptic tracing with rabies virus. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ian Wickersham

   Article

   Kohara et al Nat Neurosci. 2014 Feb;17(2):269-79. doi

   Promoter

   Syn

   Tags

   EGFP (Cre-dependent)

   Available since

   Dec. 18, 2018

   Availability

   Academic Institutions and Nonprofits only

3. pAAV-flex-taCasp3-TEVp (AAV1)

   Viral Prep

   #45580-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Jim Wells, Nirao Shah

   Article

   Yang et al Cell. 2013 May 9;153(4):896-909. doi: 10

   Promoter

   EF1a

   Tags

   None

   Available since

   Dec. 3, 2020

   Availability

   Academic Institutions and Nonprofits only

4. pAAV-flex-taCasp3-TEVp (AAV1)

   Viral Prep

   #45580-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Nirao Shah, Jim Wells

   Article

   Yang et al Cell. 2013 May 9;153(4):896-909. doi: 10

   Promoter

   EF1a

   Tags

   None

   Available since

   Dec. 3, 2020

   Availability

   Academic Institutions and Nonprofits only

5. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV1)

   Viral Prep

   #87306-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Li Zhang

   Article

   Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

   Promoter

   EF1a

   Tags

   None

   Available since

   April 18, 2019

   Availability

   Academic Institutions and Nonprofits only

6. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV1)

   Viral Prep

   #87306-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Li Zhang

   Article

   Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

   Promoter

   EF1a

   Tags

   None

   Available since

   April 18, 2019

   Availability

   Academic Institutions and Nonprofits only

7. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV8)

   Viral Prep

   #87306-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Li Zhang

   Article

   Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

   Promoter

   EF1a

   Tags

   None

   Available since

   Jan. 26, 2021

   Availability

   Academic Institutions and Nonprofits only

8. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV8)

   Viral Prep

   #87306-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Li Zhang

   Article

   Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

   Promoter

   EF1a

   Tags

   None

   Available since

   Jan. 26, 2021

   Availability

   Academic Institutions and Nonprofits only

9. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV9)

   Viral Prep

   #87306-AAV9

   Purpose

   Ready-to-use AAV9 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Li Zhang

   Article

   Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

   Promoter

   EF1a

   Tags

   None

   Available since

   Jan. 26, 2021

   Availability

   Academic Institutions and Nonprofits only

10. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV9)

    Viral Prep

    #87306-AAV9

    Purpose

    Ready-to-use AAV9 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Li Zhang

    Article

    Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

    Promoter

    EF1a

    Tags

    None

    Available since

    Jan. 26, 2021

    Availability

    Academic Institutions and Nonprofits only

11. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV2)

    Viral Prep

    #87306-AAV2

    Purpose

    Ready-to-use AAV2 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Li Zhang

    Article

    Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

    Promoter

    EF1a

    Tags

    None

    Available since

    Aug. 24, 2020

    Availability

    Academic Institutions and Nonprofits only

12. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV2)

    Viral Prep

    #87306-AAV2

    Purpose

    Ready-to-use AAV2 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Li Zhang

    Article

    Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

    Promoter

    EF1a

    Tags

    None

    Available since

    Aug. 24, 2020

    Availability

    Academic Institutions and Nonprofits only

13. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV5)

    Viral Prep

    #87306-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Li Zhang

    Article

    Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

    Promoter

    EF1a

    Tags

    None

    Available since

    July 22, 2020

    Availability

    Academic Institutions and Nonprofits only

14. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV5)

    Viral Prep

    #87306-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Li Zhang

    Article

    Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

    Promoter

    EF1a

    Tags

    None

    Available since

    July 22, 2020

    Availability

    Academic Institutions and Nonprofits only

15. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV Retrograde)

    Viral Prep

    #87306-AAVrg

    Purpose

    Ready-to-use AAV Retrograde particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Li Zhang

    Article

    Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

    Promoter

    EF1a

    Tags

    None

    Available since

    July 22, 2020

    Availability

    Academic Institutions and Nonprofits only

16. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV Retrograde)

    Viral Prep

    #87306-AAVrg

    Purpose

    Ready-to-use AAV Retrograde particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Li Zhang

    Article

    Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

    Promoter

    EF1a

    Tags

    None

    Available since

    July 22, 2020

    Availability

    Academic Institutions and Nonprofits only

17. Human CRISPRa sgRNA library Calabrese in backbone XPR_502 (P65 HSF), Set A (Lentiviral Prep)

    Viral Prep

    #92379-LV

    Purpose

    Ready-to-use Lentiviral Prep particles produced from Human CRISPRa sgRNA library Calabrese in backbone XPR_502 (P65 HSF), Set A (#92379). In addition to the viral particles, you will also receive purified Human CRISPRa sgRNA library Calabrese in backbone XPR_502 (P65 HSF), Set A plasmid DNA. Ready-to-use lentiviral pooled library for CRISPR activation screening in human cells. Contains 56,762 sgRNAs, targeting 18,885 genes. Concentrated lentiviral particles carrying set A of the Calabrese human CRISPRa sgRNA activation library in backbone XPR_502 (P65 HSF) .

    Depositor

    David Root, John Doench

    Article

    Sanson et al Nat Commun. 2018 Dec 21;9(1):5416. doi:

    Promoter

    Tags

    None

    Available since

    Aug. 3, 2017

    Availability

    Academic Institutions and Nonprofits only

18. Human CRISPRa sgRNA library Calabrese in backbone XPR_502 (P65 HSF), Set A (Lentiviral Prep)

    Viral Prep

    #92379-LV

    Purpose

    Ready-to-use Lentiviral Prep particles produced from Human CRISPRa sgRNA library Calabrese in backbone XPR_502 (P65 HSF), Set A (#92379). In addition to the viral particles, you will also receive purified Human CRISPRa sgRNA library Calabrese in backbone XPR_502 (P65 HSF), Set A plasmid DNA. Ready-to-use lentiviral pooled library for CRISPR activation screening in human cells. Contains 56,762 sgRNAs, targeting 18,885 genes. Concentrated lentiviral particles carrying set A of the Calabrese human CRISPRa sgRNA activation library in backbone XPR_502 (P65 HSF) .

    Depositor

    David Root, John Doench

    Article

    Sanson et al Nat Commun. 2018 Dec 21;9(1):5416. doi:

    Promoter

    Tags

    None

    Available since

    Aug. 3, 2017

    Availability

    Academic Institutions and Nonprofits only

19. pAAV CD68-hM4D(Gi)-mCherry (AAV9)

    Viral Prep

    #75033-AAV9

    Purpose

    Ready-to-use AAV9 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Bryan Roth

    Article

    Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

    Promoter

    CD68

    Tags

    mCherry

    Available since

    Sept. 27, 2023

    Availability

    Academic Institutions and Nonprofits only

20. pAAV CD68-hM4D(Gi)-mCherry (AAV9)

    Viral Prep

    #75033-AAV9

    Purpose

    Ready-to-use AAV9 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Bryan Roth

    Article

    Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

    Promoter

    CD68

    Tags

    mCherry

    Available since

    Sept. 27, 2023

    Availability

    Academic Institutions and Nonprofits only